IP Library Granted Patent US 7,935,818
Granted Patent B2
US 7,935,818 · App. 11/820,724 · Granted May 3, 2011

Process for the preparation and purification of valgancyclovir hydrochloride

Assignee: Fidia Farmaceutici S.p.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,935,818
App. No.
11/820,724
Granted
May 3, 2011
Kind
B2
Abstract

A process for the preparation of valgancyclovir which comprises: a) reacting a compound of formula 7, in an aprotic solvent, in the presence of a condensing agent, with a compound of formula 8, wherein R 1 , and R 2 may be, each independently, hydrogen, an halogen atom or an hydroxyl group; the double bond may either be in the E or Z configuration or a mixture thereof to yield a compound of formula 9 b) mild hydrolysis of compound obtained in a) to give valgancyclovir.

Claims (11)

1. A process for the preparation of valgancyclovir hydrochloride which comprises:

a) reacting a compound of formula 7,

in an aprotic solvent, in the presence of a condensing agent, with a compound of formula 8,

wherein R 1 , and R 2 may be, each independently, hydrogen, an halogen atom or an hydroxyl group; the double bond may either be in the E or Z configuration or a mixture thereof to yield a compound of formula 9

b) mild hydrolysis with hydrochloric acid of compound obtained in a) to give valgancyclovir hydrochloride.

2. A process according to claim 1 , wherein the aprotic solvent is selected from tetrahydrofuran, dioxane, formamide, N,N-dimethylformamide, N,N-dimethylacetamide.

3. A process according to claim 1 wherein the condensing agent is selected from DCC, optionally in the presence of 1-hydroxybenzotriazole, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) or its hydrochloride salt-(EDAC), or N,N′-diisopropylcarbodiimide (DIC) or (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), O-(benzotrizol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU).

4. A process according to claim 1 , further including the isolation of valgancyclovir hydrochloride from the hydrolytic solution by lyophilization.

5. A process according to claim 3 which is effected in the presence of 1-hydroxybenzotriazole, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) or its hydrochloride salt (EDAC), or N,N′-diisopropylcarbodiimide (DIC) or (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP).

6. A process for producing valgancyclovir hydrochloride which comprises: mild hydrolysis of a compound of formula 9

with hydrochloric acid and precipitating gancyclovir from an aqueous solution of the hydrolysis product and isolating pure valgancyclovir hydrochloride by lyophilization.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2016
From: FIDIA FARMACEUTICI S.P.A.
To: OLON S.P.A.
Reel/Frame 039433/0699 →
MERGER Recorded Mar 24, 2011
From: SOLMAG S.P.A.
To: FIDIA FARMACEUTICI S.PA.
Reel/Frame 026018/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2007
From: BELOGI, GIANLUCA; ROSSI, ALESSIA; BEDESCHI, ANGELO; PIZZOCARO, ROBERTA
To: SOLMAG S.P.A.
Reel/Frame 020241/0931 →
Priority Claims (1)
EP 06012784 · Jun 21, 2006 · regional
Continuity (1)
Related Publication 20080076923A1 · Mar 27, 2008